The acquisition includes Microbiome Insights’ CAP-accredited Canadian laboratory and rich intellectual property, boosting Mapmygenome’s scientific prowess.
Mapmygenome, a Hyderabad-headquartered AI-driven genomic and microbiome testing company has announced a strategic acquisition of Microbiome Insights, a global leader in microbial sequencing. The acquisition includes Microbiome Insights’ CAP-accredited Canadian laboratory and rich intellectual property, boosting Mapmygenome’s scientific prowess. On how it will make a difference and the size of the deal and its funding, Anu Acharya, Founder and CEO of Mapmygenome tells Financial Express Online that “while the specific financial details of this acquisition remain private, it represents a significant internal investment in our strategic growth. Our journey towards a public listing later this year positions North America as a cornerstone of our global expansion.” This acquisition, she further explains, “not only integrates a highly respected company with over 600 valuable customers into our ecosystem, but crucially, it empowers us to extend the reach and impact of our comprehensive genomics portfolio throughout the North American market, ultimately contributing to better health outcomes.”
A media release issued by the company says, “having supported over 600 global clients with over 1,000 cutting-edge microbiome studies, Microbiome Insights is a leading partner for academic, clinical, and industry researchers. Its founders, Dr. Brett Finlay, Dr. William Mohn, and Malcolm Kendall, are recognized global experts.
Microbiome Insights, the release adds, “will maintain its role as a premier CRO, empowering global research. Simultaneously, Mapmygenome will introduce its integrated genomics and microbiome testing services to North America, making holistic, data-driven health solutions more accessible.”
The release quotes Acharya saying: “The human microbiome is pivotal to health, and this acquisition positions us as a leader in this area. We gain exceptional expertise in metagenomics, transcriptomics, and targeted metabolomics to serve academic, biotech, and clinical sectors.” Also, “this accelerates our North American footprint aligning with our strategic vision of growth through targeted acquisitions leading up to our listing on the Indian market later this year”
Malcolm Kendall, CEO of Microbiome Insights is quoted saying: “Joining forces with Mapmygenome, provides the resources and capabilities to offer higher quality services to our clients and accelerate growth. The combination of their expertise in AI-driven genomics solutions and our deep microbiome expertise will result in a new standard of cutting-edge services for clients worldwide.”
